SCHEMBL1465255

SCHEMBL1465255

Cc1[c]cc(-c2cc(C)n(CC(C)O)n2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.37
HDAC4 P56524 3/20 0.37
HDAC1 Q13547 3/20 0.37
HDAC7 Q8WUI4 3/20 0.37
HDAC2 Q92769 3/20 0.37
HDAC10 Q969S8 3/20 0.37
HDAC11 Q96DB2 3/20 0.37
HDAC8 Q9BY41 3/20 0.37
HDAC6 Q9UBN7 3/20 0.37
HDAC9 Q9UKV0 3/20 0.37
HDAC5 Q9UQL6 3/20 0.37
NCOR2 Q9Y618 3/20 0.37
LMNA P02545 3/20 0.35
APAF1 O14727 1/20 0.35
POLB P06746 1/20 0.35
P2RX7 Q99572 4/20 0.33
RORC P51449 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1226661 0.87 HPGD (0.36) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1226732 0.87 HPGD (0.36) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1226624 0.84 KDM4E (0.42) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1226333 0.84 KDM4E (0.42) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1225793 0.84 KDM4E (0.42) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1465254 0.81 HDAC3 (0.36) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3346573 0.76 P2RX7 (0.37) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3342803 0.76 P2RX7 (0.37) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3346111 0.76 P2RX7 (0.37) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1226652 0.73 POLB (0.46) POLBMEN1KMT2AKDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110071143-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS BROTHERTON-PLEISS CHRISTINE E 2011-03-24 US claimed
US-8871760-B2 [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators ROCHE PALO ALTO LLC (US) 2014-10-28 US disclosed
EP-2480545-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 EP disclosed
WO-2011033055-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-24 WO disclosed
US-20110071143-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS BROTHERTON-PLEISS CHRISTINE E 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071143-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS P2RX3, P2RX7, P2RX1 HDAC3 1389/4885HDAC4 2863/4885HDAC1 2542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.